{"entity":{"id":"nct06505837","kind":"trial","name":"JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）","aka":[],"tldr":"A phase 3 trial of pemetrexed and toripalimab in lung cancer, run by Shanghai Junshi Bioscience Co., Ltd., active but no longer recruiting.","summary":"JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC） is a phase 3, randomised interventional study registered as NCT06505837 by Shanghai Junshi Bioscience Co., Ltd., with a registry enrolment figure of 395 participants, started 2024-07-11 and due to reach its primary completion in 2026-06-30. Interventions recorded: JS001sc (360mg Subcutaneous injection) and pemetrexed/platinum-containing chemotherapy; JS001 (240mg intravenous infusion) and pemetrexed/platinum-containing chemotherapy. Conditions listed: Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer. Primary outcome: Observed serum Ctrough at Cycle 1; Model-predicted area under the concentration-time curve(AUC) from 0 to 21 days at Cycle 1. Lung eligibility wording from the registry: \"Histologically or cytologically confirmed relapsed or metastatic non-squamous NSCLC\". Sites: China. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06505837","url":"https://clinicaltrials.gov/study/NCT06505837"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy"],"targets":[],"drugs":["pemetrexed","toripalimab"],"companies":["junshi"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06505837","phase":"3","setting":"Open-Label, Randomized, Phase III Clinical Study Comparing the Pharmacokinetic Profile, Efficacy, and Safety of JS001sc and JS001 in Combination With Standard Chemotherapy as First-Line Treatment for Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","enrolled":395,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06505837/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"},{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"company":[{"id":"junshi","kind":"company","name":"Shanghai Junshi Biosciences","route":"/companies/junshi/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}